Midatech Pharma PLC
("Midatech" or the "Company")
Midatech Pharma US Announces Partnership with R-Pharm US to Co-promote Zuplenz ® (ondansetron) oral soluble film and Oravig ® (miconazole) orally-dissolving buccal tablet
~ Partnership provides additional reach and frequency within the oncology market ~
~ Deal broadens Zuplenz and Oravig account call points ~
ABINGDON, United Kingdom and OXFORDSHIRE, United Kingdom, Sept. 21, 2016 (GLOBE NEWSWIRE) -- Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products in oncology, immunology and other therapeutic areas, today announced that its US subsidiary, Midatech Pharma US, has finalised a co-promotion agreement with R-Pharm US LLC providing additional reach and frequency for the promotion of Zuplenz and Oravig to oncology accounts across the US.
Under the terms of the agreement, R-Pharm will promote Zuplenz and Oravig in accounts that are not currently in the Midatech Pharma US call universe as well as provide additional promotion in accounts where Midatech currently markets its oncology supportive care product portfolio.
David R. Benharris, President of Midatech Pharma US, said: "We are extremely excited to add a valued partner in R-Pharm, who can provide additional promotional reach into new accounts as well as supplemental frequency to additional call points in our targeted offices. Our products, as with many pharmaceuticals products, are detail sensitive. The partnership with R-Pharm provides an enriched share of voice to further bolster our ongoing commercial efforts for both Zuplenz and Oravig."
Mark Pavoa, President and Chief Executive Officer of R-Pharm US, said: "Zuplenz and Oravig are complementary to our oncology franchise, which includes Ixempra®. Cancer patients and treatment teams face many challenges as they battle the disease, and we are proud to represent these two additional potential solutions."
Demetrios Kydonieus, President and Chief Business Officer of R-Pharm US, commented: "Adding Zuplenz and Oravig to our existing portfolio allows us to leverage our commercialisation investment and to increase the value we bring to patients and the medical offices we serve."
Zuplenz is the only oral soluble film formulation of the 5-HT3 receptor antagonist ondansetron, indicated for the prevention of nausea and vomiting associated with the use of highly and moderately emetogenic cancer chemotherapies, radiotherapy, and in postoperative patients.
Oravig is the only once-daily local therapy available for treatment of oral thrush in adults. All other currently marketed, localised therapies for oral thrush require patients to take/administer their treatment a minimum of four times daily.
R-Pharm will begin promoting both Oravig and Zuplenz in January of 2017.
- ENDS -
For more information, please contact:
Midatech Pharma PLC
Jim Phillips, CEO
Tel: +44 (0)1235 888300
Panmure Gordon (UK) Limited (Nominated Adviser and Broker)
Freddy Crossley / Atholl Tweedie / Duncan Monteith
Tel: +44 (0)20 7886 2500
Consilium Strategic Communications (Financial PR)
Mary-Jane Elliott / Ivar Milligan / Matthew Neal / Hendrik Thys
Tel: +44 (0)20 3709 5700
Westwicke Partners (US Investor Relations)
Tel: +1 339 970 2843
Notes for Editors
About Midatech Pharma PLC
Midatech is an international specialty pharmaceutical company focused on oncology and other therapeutic areas with a commercial platform and four marketed products in the US. Midatech's strategy is to develop products in-house in oncology and with partners in other indications, and to accelerate growth organically and through strategic acquisitions. The Company's R&D activities are supported by two breakthrough drug delivery technologies. The Group, listed on AIM: MTPH and Nasdaq: MTP, employs c.100 staff in four countries. For further company information see: www.midatechpharma.com
About R-Pharm US
R-Pharm US is a fully integrated specialty pharmaceutical company focused on the development and commercialization of medicines to treat cancer and chronic immune diseases. For further company information see: www.rpharm-us.com
For full prescribing information, including approve indications, potential side effects and other warnings on Ixempra, please visit www.ixempra.com
Certain statements in this press release may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom and/or United States. Such forward-looking statements include, but are not limited to, statements regarding the ability of Midatech to successfully commercialise any of its products. Any forward-looking statements are based on currently available competitive, financial and economic data together with management's views and assumptions regarding future events and business performance as of the time the statements are made and are subject to risks and uncertainties. We wish to caution you that there are some known and unknown factors that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. For a complete discussion of Risk Factors, please refer to the Company's Form 20-F Annual Report filing to be found at www.midatechpharma.com/investors/financial-reports.html
Reference should be made to those documents that Midatech shall file from time to time or announcements that may be made by Midatech in accordance with the London Stock Exchange AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs") and the rules and regulations promulgated by the US Securities and Exchange Commission, which contains and identifies other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Midatech are expressly qualified in their entirety by the cautionary statements above. Except as may be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, Midatech does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise arising.
Source:Midatech Pharma Plc